|
Intercell AG was a biotechnology company based in Vienna which focused on the development of modern prophylactic and therapeutic vaccines against infectious diseases. Intercell was formed in 1998 as a spin-off of the Research Institute of Molecular Pathology (IMP) in Vienna.〔 (【引用サイトリンク】title=Research Institute of Molecular Pathology (IMP) - About the IMP > History ) 〕 It employs 400 people in Austria, Scotland and the United States. It has been listed on the Vienna Stock Exchange since February 28, 2005. In 2008, Intercell signaled its intent to acquire Maryland-based Iomai, a developer of needle-free vaccination technology. Intercell cooperates with pharmaceutical companies like Novartis, Merck and Sanofi-Aventis on vaccine production. The most important projects of Intercell are: * Vaccine against Japanese encephalitis (approved in Europe, America and Australia)〔 〕〔 〕〔 〕 * Therapeutic vaccine against hepatitis C (in clinical phase II)〔 〕 * Antigen identification program and adjuvant technologies. * Vaccine Enhancement Patch to improve prevention against pandemic influenza (in collaboration with U.S. Department of Health and Human Services, in clinical phase II) ==References== 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Intercell」の詳細全文を読む スポンサード リンク
|